RE:hope springs eternalThis is not the same stock as in the blue sky days when Jason said it was one stock he would safely invest his grandma's money in! Jason could not predict the CMA and commercial payor and price mix problems. It was a 10%+ hit to revenues both in terms of the following year (2018) and its impact of course on future levels of reimbursement. That uncertainty remains as there are annual reviews, and this fact continues to be reflected in the trading volumes and patterns and sentiment. However company has always made up for this with organic and acquisition growth, has always been CF positive and we have the prospect of these factors predominating (I did not re-check impact on margins but I presume, apart from 2018 vs 2017 these are fine.)
I do not know what will make share price accelerate apart from unimpeded, strong growth. THey are moving to 100% ownership and possibly the MAC program (due to be updated on in near term) will bring about even stronger growth. They als have the NCIB. Maybe they will get to a dividend payment. But the cloud of uncertainty expereinced in 2017/18 will not be removed.